|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 244.31 USD | +1.52% |
|
+1.09% | +33.77% |
| 06-29 | Axsome Therapeutics, Inc.(NasdaqGM:AXSM) dropped from Russell 2000 Index | CI |
| 06-29 | Axsome Therapeutics, Inc.(NasdaqGM:AXSM) added to Russell Midcap Growth Benchmark | CI |
Company Valuation: Axsome Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,424 | 3,349 | 3,766 | 4,100 | 9,207 | 12,572 | - | - |
| Change | - | 135.22% | 12.44% | 8.87% | 124.55% | 36.54% | - | - |
| Enterprise Value (EV) 1 | 1,387 | 3,243 | 3,558 | 3,966 | 9,072 | 12,461 | 12,178 | 11,601 |
| Change | - | 133.87% | 9.72% | 11.46% | 128.76% | 37.36% | -2.27% | -4.74% |
| P/E | -10.9x | -16.8x | -15.1x | -14.1x | -49.6x | -124x | 42.8x | 16.8x |
| PBR | 90.9x | 30.6x | 19.7x | 72.2x | 105x | 12,940x | 42.4x | 14.9x |
| PEG | - | -0.5x | -1x | -1x | 1.3x | 2.7x | -0x | 0x |
| Capitalization / Revenue | - | 66.9x | 13.9x | 10.6x | 14.4x | 12.8x | 7.87x | 5.49x |
| EV / Revenue | - | 64.8x | 13.1x | 10.3x | 14.2x | 12.6x | 7.62x | 5.06x |
| EV / EBITDA | -11.1x | -18.5x | -15.8x | -14.5x | -56.7x | -112x | 51.5x | 21.8x |
| EV / EBIT | -11.1x | -18x | -15.3x | -14.1x | -54.4x | -123x | 35.4x | 12.7x |
| EV / FCF | -12.8x | -27.7x | -24.4x | -30.8x | -96.6x | -206x | 33.4x | 17.1x |
| FCF Yield | -7.83% | -3.61% | -4.09% | -3.24% | -1.03% | -0.48% | 2.99% | 5.84% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.47 | -4.6 | -5.27 | -5.99 | -3.68 | -1.971 | 5.713 | 14.56 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 50.04 | 270.6 | 385.7 | 638.5 | 985.3 | 1,598 | 2,291 |
| EBITDA 1 | -124.6 | -175.4 | -225 | -273.6 | -159.9 | -111.2 | 236.3 | 531.6 |
| EBIT 1 | -124.7 | -179.8 | -231.8 | -280.6 | -166.8 | -101.2 | 344.4 | 914.7 |
| Net income 1 | -130.4 | -187.1 | -239.2 | -287.2 | -183.2 | -102.3 | 315.2 | 812.6 |
| Net Debt 1 | -37.38 | -106.6 | -208.1 | -134.6 | -135.2 | -110.7 | -393.8 | -970.8 |
| Reference price 2 | 37.78 | 77.13 | 79.59 | 84.61 | 182.64 | 244.31 | 244.31 | 244.31 |
| Nbr of stocks (in thousands) | 37,692 | 43,426 | 47,320 | 48,462 | 50,413 | 51,460 | - | - |
| Announcement Date | 01/03/22 | 27/02/23 | 20/02/24 | 18/02/25 | 23/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -123.95x | 12.65x | -112.04x | -.--% | 12.57B | |
| 16.94x | 3.69x | 9.97x | 0.6% | 66.56B | |
| 27.98x | 5.76x | 16.9x | 0.56% | 56.51B | |
| 35.25x | 11.95x | 22.63x | -.--% | 42.98B | |
| -45.47x | 3.2x | 9.47x | 3.37% | 40.46B | |
| 34.9x | 3.71x | 11.39x | -.--% | 31.91B | |
| -9.24x | 13.4x | -8.22x | -.--% | 31.65B | |
| 16.96x | 3.25x | 9.83x | -.--% | 23.35B | |
| 55.23x | 6.16x | 42.67x | -.--% | 19.46B | |
| 26.86x | 5.49x | 14.73x | -.--% | 17.18B | |
| Average | 3.54x | 6.92x | 1.73x | 0.45% | 34.26B | |
| Weighted average by Cap. | 10.44x | 6.44x | 8.70x | 0.61% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AXSM Stock
- Valuation Axsome Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
